

Scott A. Fretzin, MD

Dawes Fretzin Clinical Research Group, LLC
7910 North Shadeland Avenue
Indianapolis, Indiana 46250
Phone (317) 516-5030
Fax (317) 516-5031
Email: DFCRGFretzin@ecommunity.com

Dawes Fretzin Dermatology Group, LLC
7910 North Shadeland Avenue
Indianapolis, Indiana 46250
Phone (317) 516-5000
Fax (317) 516-5031

Education

Indiana University School of Medicine (Indianapolis, IN)
Dermatology Residency, 1997

University of Chicago Pritzker School of Medicine (Chicago, IL)
Internal Medicine Internship, 1994

University of Chicago Pritzker School of Medicine (Chicago, IL)
Medical Doctorate, 1993

Washington University (St. Louis, MO)
Bachelor of Arts in Philosophy, 1989

Professional Experience

Marian University (Indianapolis, IN)
Clinical Assistant Professor, March 2016- Present

Dawes Fretzin Clinical Research Group, LLC (Indianapolis, IN)
Investigator, 2004-Present


Dawes Fretzin Dermatology Group, LLC (Indianapolis, IN)
Dermatologist, 1999-Present
Investigator, 2000-Present

Indiana University School of Medicine (Indianapolis, IN)
Volunteer Assistant Professor Clinical Dermatology, May 2011- Present

Bellflower County Clinic (Indianapolis, IN)
Dermatologist (part-time), 1997-April 2013

Indiana University School of Medicine (Indianapolis, IN)
Clinical Assistant Professor, 1997- May 2011

Dawes Dermatology Group (Indianapolis, IN)
Dermatologist, 1997-99



Honors and Awards

1996 Honorable Mention, Young Investigators Competition, Dermatol Surg
1992 Alpha Omega Alpha (AOA)
1989 Phi Beta Kappa
1989 Graduate with College Honors
1988 Genetics Society of America Summer Research Fellowship
1987-88 Scholarship and Leadership Award, Kappa Sigma National Fraternity

Scott A. Fretzin, MD

Clinical Study Experience

Sponsor: Celgene **Phase: 3**
A PHASE 3B, MULTI CENTER, OPEN-LABEL LONGTERM EXTENSION STUDY OF APREMILAST (CC- 10004) IN PEDIATRIC SUBJECTS FROM 6 THROUGH 17 YEARS OF AGE WITH MODERATE TO SEVERE PLAQUE PSORIASIS
July 2019- present

Sponsor: Arcutis **Phase: 2b**
ARQ-154-204: A Phase 2b, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-154 Foam 0.3% Administered QD Adolescents and Adults with Scalp and Body Psoriasis
October 2019- Present

Sponsor: Abbvie **Phase: 3b**
M19-164: A Phase 3b, Multicenter, Interventional, Open Label Study of adult patients with moderate to severe plaque psoriasis who have a suboptimal response to secukinumab or ixekinumab and are switched to risankizumab
October 2019- Present

Sponsor: Arcutis **Phase: 3**
A Phase 3, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.3% Administered QD in Subjects with Chronic Plaque Psoriasis
October 2019- Present

Sponsor: Arcutis **Phase: 3**
A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.3% in Subjects with Chronic Plaque Psoriasis who have Completed Preeceding Studies ARG-151-301 or ARQ-151-302
ARQ-151-306
December 2019- Present

Sponsor: Arcutis **Phase: 3**
A Phase 3, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.3% Administered QD in Subjects with Chronic Plaque Psoriasis
October 2019- Present

Sponsor: Celgene **Phase: 3**
CC-10004-PSOR-025: A PHASE 3, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF APREMILAST (CC-10004) IN SUBJECTS WITH MODERATE TO SEVERE GENITAL PSORIASIS
August 2019- Present

Sponsor: Lilly **Phase: 1**
J1P-MC-KFAC: A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3471851 in Patients with Psoriasis
November 2019- Present

Sponsor: Dermavant **Phase: 2/3**
DMVT-505-3003 A Long-Term, Open-Label, Extension Study to Evaluate the safety of Tapinarof cream,

Scott A. Fretzin, MD

1% for the Treatment of Plaque Psoriasis in Adults
December 2019- Present

Sponsor: Dermavant

Phase: 3

DMVT-505-3001 A Phase 3 Efficacy and Safety of Tapinarof for the Treatment of Plaque Psoriasis in Adults

January 2019- Present

Sponsor: PCORI LITE PCS

Phase: 2/3

A pragmatic trial of home versus based narrow band ultraviolet B phototherapy for the treatment of psoriasis

April 2019- Present

Sponsor: Lilly

Phase: 2/3

Protocol I6T-MC-AMBK

An Open-Label Evaluation of Mirikizumab following Subcutaneous Administration Using Prefilled Syringe or Auto Injector in Patients with Moderate-to-Severe Plaque Psoriasis-I6T-MC-AMBK

February 2019- Present

Sponsor: Novartis

Phase 2/3

Novartis Pharmaceuticals trial entitled: a randomized, double-blind, multicenter study assessing short (16 weeks) and long-term efficacy (up to 1 year), safety, and tolerability of 2 subcutaneous secukinumab dose regimens in adult patients with moderate to severe hidradenitis suppurativa (SUNRISE)

Protocol No: CAIN457M2302

March 2019- Present

Sponsor: Akros Pharma

Phase: 2/3

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel group Study to Evaluate the Efficacy and Safety of JTE-451 Administered for 16 Weeks in Subjects with Moderate to Severe Plaque Psoriasis (IMPACT-PS)

February 2019- Present

Sponsor: Menlo Therapeutics

Phase: 2/3

A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Chronic Pruritus of Unknown Origin.

January 2019- Present

Sponsor: Anaptys Bio

Phase: 2

A phase II, Randomized, Placebo-controlled, Double-blind, Multiple Dose study to Evaluate the Efficacy and Safety of ANB019 in Subjects with Palmoplantar Pustulosis.

November 2018- Present

Sponsor: Anaptys Bio

Phase: 2/3

A Single Arm Multiple Dose Study to Assess the Efficacy and Safety of ANB019 in Subjects with Generalized Pustular Psoriasis

November 2018- Present

Sponsor: Celgene

Phase: 3

A PHASE 3, MULTI-CENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF APREMILAST (CC-10004) IN SUBJECTS WITH MILD TO MODERATE PLAQUE PSORIASIS

September 2018- Present

Sponsor: Celgene

Phase: 3

A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE- BLIND, PLACEBO-CONTROLLED STUDY TO

Scott A. Fretzin, MD

ASSESS THE EFFICACY AND SAFETY OF APREMILAST (CC-10004) IN PEDIATRIC SUBJECTS FROM 6 THROUGH 17 YEARS OF AGE WITH MODERATE TO SEVERE PLAQUE PSORIASIS
September 2018- Present

Sponsor: Novartis

Phase:

Novartis Pharmaceuticals trial entitled: A randomized, double-blind, placebo- and active controlled multicenter trial to demonstrate efficacy of subcutaneous secukinumab compared to placebo and etanercept (in a single-blinded arm) after twelve weeks of treatment, and to assess the safety, tolerability, and long-term efficacy in subjects from 6 to less than 18 years of age with severe chronic plaque psoriasis.

February 2018- October 2018

Sponsor: Lilly

Phase: 4

I1F-MC-RHCR

Phase IV

A 24-Week Multicenter, Randomized, Double-Blind, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis

March 2019- Present

Sponsor: Novartis

Phase: 3

Novartis Pharmaceuticals trial entitled: A randomized, double-blind, multicenter study assessing short (16 weeks) and long-term efficacy (up to 1 year), safety, and tolerability of sub-cutaneous secukinumab in subjects of body weight 90 kg or higher with moderate to severe chronic plaque-type psoriasis

June 2018- Present

Sponsor: Lilly

Phase: 3

I6T-MC-AMAH A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of Mirikizumab in Patients with Moderate-to-Severe Plaque Psoriasis

OASIS-3

June 2018- Present

Sponsor: BI

Phase: 2

Phase II evaluation of safety, tolerability, and efficacy of BI 730357 in patients with moderate-to-severe plaque psoriasis.- 1407-0030

August 2018- Present

Sponsor: Eli Lilly

Phase: 3

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Mirikizumab to Secukinumab and Placebo in Patients with Moderate-to-Severe Plaque Psoriasis- I6T-MC-AMAJ

June 2018- Present

Sponsor: Dr. Reddy's Lab

Phase: 2

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, 24-week Study to Assess the Efficacy and Safety of PPC-06 (Tepilamide Fumarate) Extended Release Tablets in Subjects with Moderate to Severe Plaque Psoriasis. PPC-06-CD-004

April 2018- Present

Sponsor: Sienna

Phase: 2

An Exploratory, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of SNA-120 (Pegcantratinib) Ointment for the Symptomatic Treatment of Persistent Pruritus and Psoriasis in Subjects Being Treated with Calcipotriene Ointment. SNA-120-202

April 2018- February 2019

Scott A. Fretzin, MD

Sponsor: Allergan

Phase: 2b

A Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AGN-242428 in Patients with Plaque Psoriasis: 1957-201-001

January 2018- May 2018

Sponsor: Janssen

Phase: 3

A Multicenter, Randomized, Double-Blind Study Evaluating the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis: CNTO1959PSO3009

May 2017- October 2018

Sponsor: Novartis

Phase: 4

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to explore changes in subcutaneous adipose tissue and modulation of skin inflammation after 12 weeks of treatment with secukinumab, compared to placebo, and up to 52 weeks of treatment with secukinumab in adult patients with moderate to severe plaque psoriasis (ADIPSO): CAIN457AUS07

April 2017- June 2019

Sponsor: Pfizer

Phase: 2A

A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety and Efficacy of PF-06700841 in Subjects with Moderate to Severe Plaque Psoriasis. B7931004

March 2017- May 2018

Sponsor: Bristol-Myers Squibb

Phase: 2

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects with Moderate to Severe Psoriasis. BMS IM011011

March 2017- August 2017

Sponsor: AbbVie

Phase: 3

A Multicenter, Open-Label Study to assess the safety and efficacy of risankizuMab for maintenance in moderate to severe plaque type psoriasis. M15-997

March 2017- Present

Sponsor: Janssen

Phase: 3

A Phase III Open-Label Study to Assess the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Ustekinumab in the Treatment of Moderate to Severe Chronic Plaque Psoriasis in Pediatric Subjects ≥ 6 to < 12 Years of Age. CNTO1275PSO3013

January 2017- October 2017

Sponsor: UCB BioPharma

Phase: 2B

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose Ranging Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Bimekizumab in Adult Subjects with Moderate to Severe Chronic Plaque Psoriasis. PS0010

October 2016- June 2017

Sponsor: Eli Lilly

Phase: 1

A Multi-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3041658 in Patients with Neutrophilic Skin Diseases. I7P-MC-DSAB

September 2016-August 2019

Sponsor: Kadmon

Phase: 2

A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Evaluate the Safety,

Scott A. Fretzin, MD

Tolerability, and Efficacy of KD025 in Adult Subjects with Moderate to Severe Chronic Plaque Psoriasis who are Candidates for Systemic Therapy or Phototherapy. KD025-211
September 2016-November 2019

Sponsor: Novartis

Phase 3

A 52-week, Multicenter, Randomized, Double-Blind Study of secukinumab (300 mg) to demonstrate the efficacy as assessed by Psoriasis Area and Severity Index and Investigator's Global Assessment after 12 weeks of treatment, compared to ustekinumab, and to assess long term safety, tolerability, and efficacy in subjects with moderate to severe plaque psoriasis. CAIN457A2326

August 2016- Present

Sponsor: Evidera/Eli Lilly and Company

Phase: 4

Assessment of the Content Validity of the Psoriasis Symptoms Scale (PSS). – EVA-18225-01

June 2016- Present

Sponsor: Eli Lilly

Phase: 3

A Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of Ixekizumab Versus Placebo in Patients with Moderate-to-Severe Genital Psoriasis. – I1F-MC-RHBQ(1)

April 2016- May 2018

Sponsor: Boehringer Ingelheim

Phase:

BI 655066 versus Ustekinumab and placebo comparators in a Randomized Double-Blind Trial for Maintenance use in Moderate to severe plaque type psoriasis-2 (U1tIMMa-2) – 1311.28

March 2016 – November 2017

Sponsor: Evidera/Eli Lilly and Company

Phase: 4

Cognitive Interviewing of the Subcutaneous Administration Assessment Questionnaire (SQAQ) in Patients with Moderate to Severe Plaque Psoriasis – EVA-18225

February 2016 – June 2016

Sponsor: Promius Pharma, LLC

Phase: 3

A Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Parallel Group Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate to Severe Plaque Psoriasis for 14 Days – DFD06-CD-005

November 2015 to September 2016

Sponsor: Baxalta US, Inc./Baxalta Innovations GmbH

Phase:3

A Phase III Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects with Moderate to Severe Chronic Plaque-type Psoriasis – 911401

October 2015 to October 2017

Sponsor: Eli Lilly and Company

Phase: 3

A Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of Ixekizumab Dosing Regimens in Patients with Moderate-to-Severe Plaque Psoriasis – I1F-MC-RHBP

August 2015 to June 2017

Sponsor: Corrona, LLC

Phase: 1

Corrona Psoriasis Registry – Corrona PSO-500

July 2015 to Present

Sponsor: UCB Biopharma, SPRL / Dermira, Inc.

Phase: 3

A Phase III, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-and-Active-Controlled Study Followed by a Placebo-Controlled Maintenance Period and Open-Label Follow-up to Evaluate the Efficacy and Safety of Certolizumab Pegol in Subjects with Moderate to Severe Chronic Plaque Psoriasis – PSO003

May 2015 to Present

Scott A. Fretzin, MD

Sponsor: Amgen, Inc.

Phase: 1

A Prospective, Observational Study to Estimate the Proportion of Subjects With Plaque Psoriasis who Achieve Complete Clearance on Biologics - 20120363

May 2015 to April 2017

Sponsor: TOLMAR, Inc.

Phase: 3

A Double-Blind, Randomized, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing TOLMAR Calcipotriene Ointment, 0.005% to Reference Listed Drug in the Treatment of Plaque Psoriasis – TOL2707A

March 2015 to June 2016

Sponsor: Amgen, Inc.

Phase: 4

A Single-arm Study to Assess the Immunogenicity and Safety of Etanercept Produced Using a Modified Process in Subjects With Plaque Psoriasis. Phase 4 Study - 20101177

February 2015 to March 2016

Sponsor: Pfizer, Inc.

Phase: 2

A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety and Efficacy of PF-04965842 in Subjects with Moderate to Severe Psoriasis – B7451005

November 2014 to September 2015

Sponsor: Janssen Research and Development, LLC

Phase: 2

A Phase II Multicenter, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Toreforant (JNJ-38518168) for the Treatment of Subjects with Moderate to Severe Plaque type Psoriasis – 38518168PSO2001

November 2014 to January 2016

Sponsor: Janssen Research and Development, LLC

Phase: 3

A Phase III, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Guselkumab for the Treatment of Subjects With Moderate to Severe Plaque-Type Psoriasis and Inadequate Response to Ustekinumab – CNTO1959PSO3003

November 2014 to July 2016

Sponsor: Janssen Research and Development, LLC

Phase: 3

A Phase III, Multicenter, Randomized, Double-blind, Placebo and Active Comparator-controlled Study Evaluating the Efficacy and Safety of Guselkumab in the Treatment of Subjects with Moderate to Severe Plaque-type Psoriasis Incorporating Randomized Withdrawal and Retreatment – CNTO1959PSO3002

November 2014 to Present

Sponsor: Novartis Institutes for BioMedical

A Randomized, Double-Blind, Placebo and Positive Controlled, Single and Multiple Dose Study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of CJM112 in chronic plaque-type psoriasis patients – CCJM112X2101

November 2014 to January 2016

Sponsor: Hexal AG/Sandoz, Inc.

Phase: 3

A Randomized, Double-Blind, Multicenter Study to demonstrate equivalent efficacy and to compare safety and immunogenicity of a biosimilar adalimumab (GP2017) and Humira® in patients with moderate to severe chronic plaque-type psoriasis – GP17-301

July 2014 to July 2016

Sponsor: Amgen, Inc.

A Study to Assess the Clinical Meaningfulness and Interpretability of Improvement in patient-reported psoriasis symptom severity over the course of treatment for chronic plaque psoriasis – 20130126 (HRA 1603A)

Scott A. Fretzin, MD

May 2014 to February 2016

Sponsor: AbGenomics **Phase: 2**

Efficacy, safety, tolerability, and pharmacokinetics of multiple doses of AbGn-168H administered by intravenous infusion to patients with moderate to severe chronic plaque psoriasis (randomized, double-blind, placebo-controlled) – 2014.002.01

May 2014 to April 2015

Sponsor: Novartis Pharmaceuticals **Phase: 3**

A 52-week, Multicenter, Randomized, Double-Blind Study of subcutaneous secukinumab to demonstrate efficacy as assessed by Psoriasis Area and Severity Index at 16 weeks of treatment compared to ustekinumab and to assess long-term safety, tolerability and efficacy in subjects with moderate to severe plaque psoriasis – CAIN457A2317

May 2014 to November 2016

Sponsor: Janssen Research and Development **Phase: 1**

Exploratory Genetic Study in Subjects with Moderate to Severe Psoriasis – NOCOMPOUNDPSO0001

March 2014 to September 2014

Sponsor: Amgen, Inc.

A Comparison of Psoriasis Symptom Severity and Health-Related Quality of Life in Patients With Clear and Almost Clear Levels of Skin Improvement – 20130127 (HRA 1889A)

October 2013 to August 2014

Sponsor: Novartis Pharmaceuticals **Phase: 3**

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Study to demonstrate the efficacy at 16 weeks of secukinumab 150 and 300 mg s.c. and to assess safety, tolerability and long-term efficacy up to 80 weeks in subjects with moderate to severe nail psoriasis – CAIN457A2313

September 2013 to April 2017

Sponsor: Novartis Pharmaceuticals **Phase: 3**

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to demonstrate the efficacy at 16 weeks of secukinumab 150 and 300 mg s.c. and to assess safety, tolerability and long-term efficacy up to 80 weeks in subjects with moderate to severe palmoplantar psoriasis – CAIN457A2312

September 2013 to April 2017

Sponsor: Maruho North American, Inc. **Phase: 3**

A Randomized, Vehicle-Controlled, Double-Blind, Parallel Group, Multi-Center Phase III Study to Evaluate the Safety and Efficacy of M518101 in Subjects with Plaque Psoriasis – M518101-US02

August 2013 to September 2015

Sponsor: AbGenomics BV **Phase:**

Efficacy, safety, tolerability, and pharmacokinetics of multiple doses of AbGn-168H administered by intravenous infusion to patients with moderate to severe chronic plaque psoriasis (randomized, double-blind, placebo-controlled) – 2012.005.01

May 2013 to April 2014

Sponsor: Eli Lilly and Company **Phase: 3**

Pharmacokinetic Evaluations of Ixekizumab following Subcutaneous Administration Using Prefilled Syringe or Auto-Injector in Patients with Moderate-to-Severe Plaque Psoriasis – I1F-MC-RHBL

April 2013 to October 2013

Sponsor: Eli Lilly and Company **Phase: 3**

A 12-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of LY2439821 to Etanercept and Placebo in Patients with Moderate to Severe Plaque Psoriasis with a Long-Term Extension Period – I1F-MC-RHBC

February 2013 to Present

Scott A. Fretzin, MD

Sponsor: Merck Sharp & Dohme Corp.

Phase: 3

A 64-Week, Phase III, Randomized, Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous SCH 900222/MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Subjects With Moderate-to-Severe Chronic Plaque Psoriasis – MK-3222-010
January 2013 to Present

Sponsor: Novartis Pharmaceuticals

Phase: 3

A Multicenter, Double-Blind and Open Label, 4-year Extension Study of subcutaneous secukinumab in prefilled syringes, assessing long-term safety, tolerability and efficacy in subjects with moderate to severe chronic plaque-type psoriasis treated with either a fixed dose regimen or on a retreatment at start of relapse regimen – CAIN457A2304E1

November 2012 to October 2017

Sponsor: Novartis Pharmaceuticals

Phase: 3

A Multicenter, Double-Blind, Randomized Withdrawal Extension Study of subcutaneous secukinumab in prefilled syringes to demonstrate long-term efficacy, safety and tolerability up to 4 years in subjects with moderate to severe chronic plaque-type psoriasis completing preceding psoriasis phase III studies with secukinumab – CAIN457A2302E1

October 2012 to November 2017

Sponsor: Celgene Corporation

Phase:3B

A Phase IIIb, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Double-Dummy, Study of the Efficacy and Safety of Apremilast (CC-10004), Etanercept, and Placebo, in Subjects with Moderate to Severe Plaque Psoriasis - CC-10004-PSOR-010

September 2012 to July 2015

Sponsor: Novartis Translational Sciences

Phase: 2

Phase II Randomized Double Blinded Placebo-Controlled, Multiple-Dose regimen study to assess the rate of histological clearance and effect on molecular pathways as well as on biomarkers of 12 months secukinumab 300 mg s.c. treated patients with chronic plaque-type psoriasis – CAIN457A2223

August 2012 to May 2015

Sponsor: Amgen, Inc.

Phase: 3

Phase III Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-3 - 20120104

August 2012 to December 2015

Sponsor: Leo Pharmaceuticals

Phase: 2

A Phase II Study comparing treatment with LEO 90100 with betamethasone dipropionate in LEO 90100 vehicle and calcipotriol in LEO 90100 vehicle in subjects with psoriasis vulgaris – LEO 90100-7

May 2012 to December 2012

Sponsor: Leo Pharmaceuticals

Phase: 2

A Phase II Study comparing treatment with LEO 90100 with calcipotriol plus betamethasone ointment, LEO 90100 vehicle and ointment vehicle in subjects with psoriasis vulgaris – LEO 90100-35

May 2012 to November 2012

Sponsor: Stiefel Laboratories, Inc.

Phase: 1

A Phase I, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Calcipotriene Foam, 0.005%, Applied Under Maximal-Use Conditions in Adolescent Subjects (Ages 12 to 16 Years) with Plaque Psoriasis – STF 115750

March 2012 to August 2017

Scott A. Fretzin, MD

Sponsor: Eli Lilly and Co., Inc.

Phase: 3

A Multicenter Study with a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance dosing Period and a Long-Term Extension Period to Evaluate the Efficacy and Safety of LY2439821 in Patients with Moderate-to-Severe Plaque Psoriasis – I1F-MC-RHAZ

February 2012 to Present

Sponsor: Janssen Research and Development, Inc.

Phase: 2

A Phase II Multicenter, Randomized, Placebo- and Active-Comparator-Controlled, Dose-Ranging Trial to Evaluate CNTO 1959 for the Treatment of Subjects with Moderate to Severe Plaque-type Psoriasis – CNTO1959PSO2001

January 2012 to November 2013

Sponsor: Novartis

Phase: 3

A Randomized, Double-Blind, Multicenter Study of subcutaneous secukinumab, assessing Psoriasis Area and Severity Index (PASI) response and maintenance of response in subjects with moderate to severe chronic plaque-type psoriasis on either a fixed dose regimen or on a retreatment at start of relapse regimen. (SCULPTURE) – CAIN 457A2304

October 2011 to September 2013

Sponsor: Novartis

Phase: 3

A Randomized, Double-Blind, Double-Dummy, Placebo Controlled, Multicenter Study of subcutaneous secukinumab to demonstrate efficacy after twelve weeks of treatment, compared to placebo and etanercept, and to assess the safety, tolerability and long-term efficacy up to one year in subjects with moderate to severe chronic plaque-type psoriasis. (FIXTURE) – CAIN457A2303

September 2011 to October 2013

Sponsor: Pfizer

Phase: 3

A Phase III Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy And Safety Of 2 Oral Doses Of Cp-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis – A3921078/A3921061

April 2011 to October 2016

Sponsor: Maruho

Phase: 2B

A Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Multi-Center Phase IIb dose finding study of M518101 in plaque psoriasis patients – M518101-US01

March 2011 to March 2012

Sponsor: Schering-Plough/Merck

Phase: 2

A Phase II, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Design, Dose-Range Finding Study of Subcutaneous SCH 900222 in Subjects With Moderate-to-Severe Chronic Plaque Psoriasis - P05495

December 2010 to January 2013

Sponsor: LEO Pharma

Phase:

Calcipotriol plus betamethasone dipropionate topical suspension compared to betamethasone dipropionate in the topical suspension vehicle, calcipotriol in the topical suspension vehicle and the topical suspension vehicle alone in psoriasis vulgaris – LEO 80185-G23

September 2010 to July 2011

Sponsor: Celgene Corporation

Phase: 3

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy And Safety Study Of Apremilast (CC-10004) In Subjects With Moderate To Severe Plaque Psoriasis – CC-1004-PSOR-008

August 2010 to October 2016

Sponsor: Wyeth

Phase: 1

A Phase I, Single Dose Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of ILV-095 Administered Subcutaneously to Subjects With Psoriasis – 3226K1-1002-WW

Scott A. Fretzin, MD

April 2010 to September 2011

Sponsor: Amgen

Phase: 3

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Adding Methotrexate to Etanercept in Subjects With Moderate to Severe Plaque Psoriasis - 20070559
February 2010 to February 2011

Sponsor: Astellas Pharma Inc.

Assessment and Tracking of Long-term Alefacept (LFA-3IgG1 Fusion Protein) Safety (ATLAS)
August 2009 to September 2012

Sponsor: Celgene Corporation

Phase: 2B

A Phase IIb, Multicenter, Treatment-Arm Blind, Safety And Efficacy 32-Week Extension Study Of Apremilast (CC-10004) In Subjects Who Completed The Treatment Phase Of The Core Study CC-10004-PSOR-005 – CC-10004-PSO-005E
April 2009 to December 2010

Sponsor: Eli Lilly and Company

Phase: 1

A Phase I, LY2439821 (Anti-IL-17 Humanized Antibody) Multiple-Dose Safety and Tolerability Study in Subjects with Psoriasis Vulgaris – I1F-MC-RHAG
January 2009 to June 2010

Sponsor: Abbott Laboratories

A 10-Year, Post-marketing, Observational Study of HUMIRA® (Adalimumab) in Patients with Chronic Plaque Psoriasis (ESPRIT) – P10-023
November 2008 to Present

Sponsor: Celgene Corporation

Phase: 2B

A Phase IIb, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-Ranging, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects with Moderate to Severe Plaque-Type Psoriasis – CC-10004-PSO-005
October 2008 to January 2010

Sponsor: Novo Nordisk

Phase: 1

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Dose, Dose-Escalation Trial of Anti-IL-20 (109-0012) 100 mg/vial in psoriatic subjects, followed by an expansion phase – NN8226-1848
October 2008 to January 2011

Sponsor: Genzyme Corporation

Phase:

A Multicenter, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Efficacy and Safety of Doxercalciferol Capsules in the Treatment of Subjects with Moderate to Severe Chronic Plaque Psoriasis – HECTPSO2507
August 2008 to 2009

Sponsor: Centocor, Inc.

Phase:

A Multicenter, Open Registry of Patients with Psoriasis Who Are Candidates for Systemic Therapy Including Biologics (PSOLAR) – C0168Z03
May 2008 to Present

Sponsor: Abbott Laboratories

Phase: 3

A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects with Moderate to Severe Chronic Plaque Psoriasis – M10-114
March 2008 to 2009

Sponsor: Abbott Laboratories

Phase: 3

A Phase III Multicenter, Open-Label Continuation Study in Moderate to Severe Chronic Plaque Psoriasis

Scott A. Fretzin, MD

Subjects who completed a Preceding Psoriasis Study with ABT-874 - M10-016
March 2008 to March 2012

Sponsor: Genentech, Inc. **Phase: 4**

A Phase IV Randomized, Double-Blind, Placebo Controlled Study To Evaluate the Safety and Efficacy of XXXXX in Adult Patients with Moderate to Severe Plaque Psoriasis with Involvement of the Scalp.
March 2008 to 2009

Sponsor: Abbott Laboratories **Phase: 3**

Open-label Study of Adalimumab in Subjects Who Have a Sub-optimal Response to Systemic Therapy or Phototherapy.
November 2007 to November 2009

Sponsor: Abbott Laboratories **Phase: 3**

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Safety and Efficacy of Two Dosing Regimens of ABT-874 to Placebo in Subjects with Moderate to Severe Chronic Plaque Psoriasis.
October 2007 to October 2009

Sponsor: Wyeth **Phase: 1**

A Phase I, Ascending Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of ILV-094 Administered Subcutaneously or Intravenously to Subjects With Psoriasis
October 2007 to June 2010

Sponsor: Centocor, Inc. **Phase: 3**

A Phase III, Multicenter, Randomized Study Comparing CNTO 1275 and Etanercept for the Treatment of Moderate to Severe Plaque Psoriasis. (T12)
March 2007 to October 2009

Sponsor: Amgen, Inc.

Observational Post-Marketing Safety Surveillance Registry of Etanercept for the Treatment of Psoriasis. (OBSERVE)
July 2006 to Present

Sponsor: Genentech, Inc. **Phase: 4**

A Phase IV Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of 1.0 mg/kg Efalizumab in Adult Subjects with Chronic Moderate or Worse Plaque Psoriasis Who Have Had an Inadequate Response to an Anti-TNF Agent
July 2006 to August 2007

Sponsor: Galderma Laboratories, L.P. **Phase: 4**

A Phase IV, Open-Label Multicenter Community-Based 4-Wk Trial to Assess Efficacy, Tolerance to Tx & Patient Satisfaction w/ CLOBEX® Spray When Used as Mono- or Add-on Therapy to Existing Systemic/Topical Agents for Tx of Plaque Psoriasis
February 2006 to June 2006

Sponsor: Centocor, Inc. **Phase: 3**

A Phase III Trial Evaluating the Efficacy and Safety of CNTO1275 in the Treatment of Subjects with Moderate to Severe Plaque-type Psoriasis. (T09)
January 2006 to December 2011

Sponsor: Genentech, Inc. **Phase: 4**

A Phase IV Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of 1.0 mg/kg Efalizumab in Adult Patients with Moderate to Severe Plaque Psoriasis Involving the Hands and/or Feet
January 2006 to April 2007

Scott A. Fretzin, MD

Sponsor: Centocor, Inc.

Phase: 3

A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Efficacy and Safety of CNTO 1275 in the Treatment of Subjects with Moderate to Severe Plaque-type to Severe Plaque-type Psoriasis (T08)

January 2006 to July 2011

Sponsor: Abbott Laboratories

Phase: 2

A Phase II, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Safety and Efficacy of Subcutaneous Injections of ABT-874 vs. Placebo in Subjects with Moderate to Severe Chronic Plaque Psoriasis.

December 2005 to September 2008

Sponsor: Astellas Pharma US, Inc.

Phase: 3

A Phase III, Long-Term, Open Label Study to Evaluate the Safety of Twice-Daily Tacrolimus Cream-B in the Treatment of Psoriasis

September 2005 to April 2007

Sponsor: Genentech, Inc.

Phase:

Raptiva Epidemiologic Study of Psoriasis Outcomes and Safety Events (RESPONSE) in Patients with Chronic Moderate to Severe Plaque Psoriasis.

April 2004 to November 2009

Sponsor: Abbott Laboratories

Phase: 3

A Phase III, Multicenter Study of the Efficacy and Safety of Long-Term Adalimumab Treatment in Subjects with Moderate to Severe Chronic Plaque Psoriasis.

October 2004 to December 2005

Sponsor: Centocor, Inc.

Phase: 3

A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Efficacy and Safety of Infliximab Induction Therapy Followed by Multiple Regimens of Maintenance Infliximab Therapy in Subjects with Plaque-type Psoriasis

February 2004 to June 2005

Sponsor: Amgen, Inc.

Phase: 4

A Multicenter, Open-Label, Prospective Study to Evaluate the Effectiveness and Safety of Etanercept in the Treatment of Subjects with Psoriasis

March 2004 to November 2004

Sponsor: Fujisawa Healthcare, Inc.

Phase: 3

A Phase III, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Once Daily 0.3% FK506 Gel versus Gel Vehicle in the Treatment of Psoriasis

March 2004 to November 2004

Sponsor: Centocor, Inc.

Phase: 2

A Phase II, Randomized, Double-blind, Placebo-controlled, Parallel Study of Single and Multiple Dosing Regimens with Subcutaneous CNTO 1275 (Human Monoclonal Antibody to IL-12) in Subjects with Moderate to Severe Psoriasis

November 2003 to June 2005

Sponsor: Genentech, Inc.

Phase: 4

An Open-Label, Multicenter Study to Evaluate the Safety of 1.0 mg/kg Subcutaneously Administered Efalizumab in Adults with Plaque Psoriasis Previously Enrolled in Study ACD2600g.

September 2002 to March 2004

Sponsor: Genentech, Inc.

Phase: 3B

A Phase IIIb, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Study to Evaluate the Safety of 1.0 mg/kg Subcutaneously Administered Efalizumab in Adults with Moderate to Severe Plaque Psoriasis Who Are Candidated for Systemic Therapy.

Scott A. Fretzin, MD

September 2002 to January 2003

Sponsor: Amgen, Inc.

Phase: 4

A Multicenter, Open-Label to Observe the Effects of XXXXX on Joint and Skin Disease in Subjects with Psoriatic Arthritis

July 2003 to August 2004

Sponsor: Novartis

Phase: 3

A randomized, double-blind, placebo- and active controlled multi-center trial to demonstrate efficacy of subcutaneous secukinumab compared to placebo and etanercept (in a single-blinded arm) after twelve weeks of treatment, and to assess the safety, tolerability, and long-term efficacy in subjects from 6 to less than 18 years of age with severe chronic plaque psoriasis. – CAIN457A2310

February 2018- October 2018

Sponsor: Evidera

Registry

Concept Elicitation and Cognitive Interviews Among Pediatric Patients with Plaque Psoriasis. – EVA-20259

December 2017- October 2018

Sponsor: Galderma

Phase: 4

A Multicenter Open Label Uncontrolled Study of the long term safety and efficacy of calcitriol 3 mcg/g ointment applied twice daily for 26 weeks in pediatric subjects (2 to 16 years and 11 months of age) with mild to moderate plaque psoriasis. – RD.06.SPR.18131

June 2016- August 2018

Sponsor: Galderma R&D, LLC

Pharmacokinetics and pharmacodynamics of calcitriol 3mcg/g ointment applied twice daily for 14 days under conditions of maximal use in pediatric subjects (2 to 12 years of age) with plaque psoriasis – RD.06.SPR.18104

April 2013 to February 2016

Sponsor: Regeneron

Phase 3

An open-label extension study to assess the long-term safety and efficacy of dupilumab in patients ≥ 6 months to < 18 years of age with Atopic dermatitis R668-AD-1434

August 2017- Present

Sponsor: Janssen

Phase: 3

A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects with Active Psoriatic Arthritis- CNTO1959PSA3002

July 2017- July 2018

Sponsor: Janssen

Phase:3

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects with Active Psoriatic Arthritis including those Previously Treated with Biologic Anti-TNF α Agent(s): CNTO1959PSA3001

July 2017- July 2018

Sponsor: AbbVie

Cross-Sectional Observational Study Evaluating Clinical Specialty Setting as Determinant of Management in Patients with Psoriatic Arthritis – H15-457

March 2017- October 2017

Sponsor: Janssen Research and Development

Phase: 2A

A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy

Scott A. Fretzin, MD

and Safety of Guselkumab in the Treatment of Subjects With Active Psoriatic Arthritis –
CNTO1959PSA2001

April 2015 to March 2017

Sponsor: Janssen Research and Development

Phase: 3

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Golimumab, an Anti-TNF α Monoclonal Antibody, Administered Intravenously, in Subjects with Active Psoriatic Arthritis –
CNTO148PSA3001

August 2014 to September 2015

Sponsor: Novartis Pharmaceuticals

Phase: 3

A Phase III, Randomized, Double-Blind, Placebo-Controlled Multicenter Study of subcutaneous secukinumab in autoinjectors, to demonstrate efficacy at 24 weeks and to assess the long term safety, tolerability and efficacy up to 3 years in subjects with active Psoriatic Arthritis – CAIN457F2318

June 2014 to September 2018

Sponsor: Celgene Corporation

Phase: 3

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Two Doses Of Apremilast (CC-10004) In Subjects With Active Psoriatic Arthritis And A Qualifying Psoriasis Lesion – CC-10004-PSA-004

January 2011 to December 2012

Sponsor: Centocor, Inc

Phase: 3

A Phase III Multicenter, Randomized, Double Blind, Placebo Controlled Trial of Ustekinumab, a Fully Human Anti IL -12p40 Monoclonal Antibody, Administered Subcutaneously in Subjects With Active Psoriatic Arthritis and Previously Treated With Biologic Anti-TNF Agent(s) – CNTO1275PSA3002

November 2010 to November 2012

Sponsor: Centocor, Inc

Phase: 3

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Ustekinumab, a Fully Human Anti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis – CNTO1275PSA3001

February 2010 to August 2013

Sponsor: Centocor, Inc.

Phase: 2

A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of XXXXX a Fully Human Anti-IL-12 Monoclonal Antibody, Administered Sub-Cutaneously, in Subjects with Active Psoriatic Arthritis. (T10)

January 2006 to November 2007

Sponsor: Lilly

Phase: 2

Protocol J1P-MC-KFAD(a) A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3471851 in Patients with Atopic Dermatitis

September 2019- Present

Sponsor: Pfizer

Phase: 3B

Protocol Number B7451050: A PHASE 3B RANDOMIZED, DOUBLE-BLIND, DOUBLE DUMMY, ACTIVE CONTROLLED MULTI-CENTER STUDY ASSESSING THE EDICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS

January 2020- Present

Sponsor: Galderma

Phase: 2/3

RD.o6.SPR.118380

Protocol Title: A Randomized, Double-Blind, Placebo-Controlled Study to Assess Immunization

Scott A. Fretzin, MD

Responses in Adult and Adolescent Subjects with Moderate-to-Severe Atopic Dermatitis Treated with Nemolizumab
December 2019- Present

Sponsor: Rapt **Phase: 1**

Title: A phase 1, randomized, double-blind, placebo-controlled, single-dose escalation, multiple-dose escalation, and food effect study of RPT193 in healthy subjects and patients with moderate to severe dermatitis

December 2019- Present

Sponsor: Abbvie **Phase: 1**

M16-049: An Open-label Multiple-Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitinib in Pediatric Subjects with Severe Atopic Dermatitis

October 2019- Present

Sponsor: Arcutis **Phase: 2**

TITLE: A Phase 2, 4-week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.05% and ARQ-151 Cream 0.15% Administered QD in Adolescent and Adult Subjects with Atopic Dermatitis

May 2019- Present

Sponsor: Galderma **Phase: 2/3**

RD.06.SPR.118161

A randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD 14152) in Subjects with Moderate-to-severe Atopic Dermatitis

July 2019- Present

Sponsor: AbbVie **Phase: 3b**

Protocol M16-046: A Phase 3b Multicenter, Randomized, Double-Blind, Double-Dummy, Active Controlled Study Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Adult Subjects with Moderate to Severe Atopic Dermatitis

May 2019- Present

Sponsor: Arcutis **Phase: 2**

TITLE: A Phase 2, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.05% and AFQ-151 Cream 0.15% Administered QD in Adolescent and Adult Subjects with Atopic Dermatitis

July 2019- Present

Sponsor: Sanofi/IQVIA

EVALUATION OF BIOMARKERS OF ATOPIC DERMATITIS IN PEDIATRIC PATIENTS WHOSE DISEASE IS NOT ADEQUATELY CONTROLLED WITH TOPICAL PRESCRIPTION THERAPIES OR WHEN THOSE THERAPIES ARE NOT MEDICALLY ADVISABLE

April 2019- Present

Sponsor: Galapagos **Phase: 2**

MORE106-CL-204 A randomized, double-blind, placebo-controlled, multicenter Phase 2 study to evaluate the safety and tolerability of subcutaneous MOR 106 administered concomitantly with topical corticosteroids for eight weeks, in adult subjects with moderate to severe atopic dermatitis

February 2019- Present

Sponsor: LEO **Phase: 1**

LP0133-1181: A phase 1 open-label, multi-center, single-arm trial to evaluate the safety and pharmacokinetics (including MUsT) of twice daily topical application of digaceticin cream for 8 weeks in adults, adolescents, and children with moderate to severe atopic dermatitis

Scott A. Fretzin, MD

February 2019- Present

Sponsor: Pfizer

Phase: 3

A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, MULTI-CENTER STUDY INVESTIGATION THE EFFICACY AND SAFETY OF PF 04965842 CO ADMINISTERED WITH BACKGROUND MEDICATED TOPICAL THERAPY IN ADOLESCENT PARTICIPANTS 12 TO <18 YEARS OF AGE WITH MODERATE-TO-SEVERE ATOPICAL DERMATITIS B7451036, site 1006

January 2019- Present

Sponsor: Ralexar

Phase: 2

A PHASE 2, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ALX-101 TOPICAL GEL ADMINISTERED TWICE DAILY IN ADULT AND ADOLESCENT SUBJECTS WITH MODERATE ATOPIC DERMATITIS

Code Number: ALX-101-ATOP-204

March 2019 – January 2020

Sponsor: Kyowa Hakko

Phase: 2

4803-006 – A Phase 2, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-Controlled Study of an Anti-OX 40 Monoclonal Antibody (KHK4083) in Subjects with Moderate to Severe Atopic Dermatitis.

December 2018- Present

Sponsor: Kiniksa

Phase: 1b

A Phase 1b, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Repeated Doses of KPL-716

October 2018- July 2019

Sponsor: Incyte

Phase: 3

A Phase 3, Double-blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults with Atopic Dermatitis

March 2019 - Present

Sponsor: Asana

Phase: 2

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ASN002 IN SUBJECTS WITH SEVERE CHRONIC HAND ECZEMA REFRACTORY TO TOPICAL CORTICOSTEROID THERAPY

November 2018-Present

Sponsor: XBiotech

Phase: 2

A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Atopic Dermatitis

Number of Patient consent: 4

February 2020- Present

Sponsor: Qurient

Phase: 2

Q301-AD-P2-US002 A MULTICENTER, RANDOMIZED, PHASE 2, DOUBLE-BLIND, VEHICLECONTROLLED, PARALLEL GROUP COMPARISON STUDY TO EVALUATE THE SAFETY AND EFFICACY OF Q301 CREAM IN ADOLESCENTS AND ADULTS WITH MILD TO MODERATE ATOPIC DERMATITIS

Number of Patient Consent: 9

September 2018- January 2020

Sponsor: BMX

Phase:

A Randomized, Placebo-Controlled, Dose-Escalation Trial to Evaluate the Safety, Clinical Effects, and Systemic Exposure of a Topical Application of BMX-010 in Subjects with Atopic Dermatitis and Plaque Psoriasis

Scott A. Fretzin, MD

August 2018- present

Sponsor: Abbvie

Phase: 3

Clinical Study Protocol M16-045: A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis

Number of Patients consented: 7

May 2018- Present

Sponsor: LEO

Phase: 3

Long-term extension trial for in patients previously treated with Tralokinumab monotherapy for moderate to severe atopic dermatitis.

November 2018- Present

Sponsor: Pfizer

Phase:3

A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-04965842 MONOTHERAPY IN SUBJECTS AGED 12 YEARS AND OLDER, WITH MODERATE TO SEVERE ATOPIC DERMATITIS- B7451013

September 2018- June 2019

Sponsor: Sanofi

Registry

Prospective, observational, longitudinal study in pediatric patients with moderate to severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not medically advisable- OBS15333

December 2018-Present

Sponsor: Asana

Phase: 2

A Phase 2, Multicenter, Open-Label Extension Study to Evaluate the long-term Safety, Tolerability and Efficacy of ASN002 in Subjects with Moderate to Severe Atopic Dermatitis.- ASN002AD-201-EXT

November 2018- Present

Sponsor: Eli Lilly

Phase: 3

A Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients with Moderate to Severe Atopic Dermatitis - I4V-MC-JAIX

January 2019- Present

Sponsor: Pfizer

Phase 3

A PHASE 3 RANDOMIZED WITHDRAWAL, DOUBLE BLIND, PLACEBO CONTROLLED, MULTI CENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OF PF 04965842 IN SUBJECTS AGED 12 YEARS AND OVER, WITH MODERATE TO SEVERE ATOPIC DERMATITIS WITH THE OPTION OF RESCUE TREATMENT IN FLARING SUBJECTS- B7451014

August 2018- Present

Sponsor: Pfizer

Phase: 3

A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-CENTER, LONG-TERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF PF-04965842, WITH OR WITHOUT TOPICAL MEDICATIONS, ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS- B7451015

June 2018- Present

Sponsor: Asana

Phase: 2B

A Randomized, Double-Blind, Placebo-Controlled, Phase 2B Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ASN002 in Subjects with Moderate to Severe Atopic Dermatitis ASN002AD-201

Scott A. Fretzin, MD

April 2018-September 2019

Sponsor: Eli Lilly

Phase: 3

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients with Moderate to Severe Atopic Dermatitis. I4V-MC-JAIW
April 2018- Present

Sponsor: Novan

Phase: 1b

A Phase 1b Multi-Center, Double-Blind, Randomized, Vehicle-Controlled Study Assessing the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of SB414 in Subjects with Atopic Dermatitis. NI-AD101
February 2018- June 2018

Sponsor: Dermira

Phase: 2b

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients with Moderate to Severe Atopic Dermatitis. DRM06-AD01
February 2018- July 2019

Sponsor: Pfizer

Phase: 3

A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Study to Evaluate the Efficacy and Safety of PF-04965842 Monotherapy in Subjects Aged 12 Years and Older, with Moderate to Severe Atopic Dermatitis. B7451012
February 2018- May 2019

Sponsor: Dermavant

Phase: 1b

Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of RVT-501 Topical Ointment in Pediatric Patients with Atopic Dermatitis. RVT-501-2007
February 2018 – August 2018

Sponsor: Pfizer

Phase: 1

A Phase 1, Randomized, Double-Blind, Therapy-Party Open, Placebo-Controlled, Dose Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single, and/or Multiple Intravenous and/or Subcutaneous Doses of PF-06817024 in Healthy Subjects who may be Mildly Atopic, Subjects with Chronic Rhinosinusitis with Nasal Polyps, and Subjects with Moderate-Severe Atopic Dermatitis. C0341001
January 2018- Present

Sponsor: Regeneron

Phase: Observation

A PROSPECTIVE OBSERVATIONAL STUDY OF ADULT PATIENTS RECEIVING DUPIXENT® FOR ATOPIC DERMATITIS- R668-AD-1762
January 2018-March 2018

Sponsor: Leo

Phase: 2

Tralokinumab monotherapy for moderate to severe atopic dermatitis: LP0162-1326
August 2017- October 2019

Sponsor: Regeneron

Phase: 2

A Randomized, Double-Blind, Placebo-Controlled Study To Investigate The Efficacy And Safety Of Dupilumab Monotherapy In Patients ≥12 To <18 Years Of Age, With Moderate-To-Severe Atopic Dermatitis: R668-AD-1526
August 2017-July 2018

Sponsor: Regeneron

Phase: 1

An Open-Label, Randomized, Actual Use Study of Dupilumab Auto-Injector Device in Patients with Atopic Dermatitis- R668-AD-1607
May 2017- April 2018

Scott A. Fretzin, MD

Sponsor: GSK

Phase: 2

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Mepolizumab Administered Subcutaneously in Subjects with Moderate to Severe Atopic Dermatitis- 205050

November 2016- January 2018

Sponsor: Incyte

Phase: 2

A Phase II, Randomized, Dose-Ranging, Vehicle-Controlled and Triamcinolone 0.1% Cream- Controlled Study to Evaluate the Safety and Efficacy of INCB018424 Phosphate Cream Applied Topically to Adults with Atopic Dermatitis.- INCB18424-206

April 2017- May 2018

Sponsor: Pfizer

Phase: 2B

A Phase IIb Randomized, Double-Blind, Placebo-Controlled, Parallel, Multicenter, Dose-Ranging, Study to Evaluate the Efficacy and Safety Profile of PF-04965842 in subjects with Moderate to Severe Atopic Dermatitis.- B7451006

April 2016- May 2017

Sponsor: GlaxoSmithKline

Phase: 2

A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis - 203121

February 2016 to March 2017

Sponsor: MedImmune, Limited

Phase: 2A

A Phase IIa, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MEDI9929 in Adult Subjects with Moderate-to-Severe Atopic Dermatitis - D5240C00001

August 2015 to September 2016

Sponsor: Regeneron Pharmaceuticals, Inc.

Phase: 3

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Investigating the Efficacy and Safety of Multiple Dupilumab Dose Regimens Administered as Monotherapy for Maintaining Treatment Response in Patients with Atopic Dermatitis - R668-AD-1415

July 2015 to February 2017

Sponsor: Regeneron Pharmaceuticals, Inc.

Phase: 3

An Open-Label Study of Dupilumab in Patients with Atopic Dermatitis Who Participated In Previous Dupilumab Clinical Trials - R668-AD-1225

June 2015 to September 2017

Sponsor: Regeneron Pharmaceuticals

Phase: 3

A Phase III Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients with Moderate-to-Severe Atopic Dermatitis – R668-AD-1334

February 2015 to June 2016

Sponsor: Regeneron Pharmaceuticals, Inc.

Phase: 2

A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults with Moderate to Severe Atopic Dermatitis Treated with Dupilumab – R668-AD-1314

September 2014 to December 2015

Sponsor: Anacor Pharmaceuticals, Inc.

Phase: 3

A Multicenter, Open-Label Study of the Long-Term Safety of AN2728 Topical Ointment, 2% in the Treatment of Children and Adolescents (Ages 2–17 Years) With Atopic Dermatitis - AN2728-AD-303

February 2014 – November 2015

Scott A. Fretzin, MD

Sponsor: Anacor Pharmaceuticals, Inc.

Phase: 3

A Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study of the Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis - AN2728-AD-302

February 2014 – August 2015

Sponsor: Chugai Pharmaceutical Co., Ltd.

Phase: 2

A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Efficacy of CIM331 in Atopic Dermatitis Patients Who Are Inadequately Controlled or Intolerant to Topical Therapy – CIM003JG

November 2013 to October 2016

Sponsor: Anacor Pharmaceuticals, Inc.

An Open-Label Study to Determine the Safety, Tolerability, and Pharmacokinetic Profile of AN2728 Ointment in Adolescents with Atopic Dermatitis – AN2728-AD-203

May 2012 to November January 2013

Sponsor: Novartis

Phase: 1

A first-in-human Study to evaluate safety and tolerability of repeated topical administrations of BPR277 ointment in healthy volunteers, and safety, tolerability, and preliminary efficacy of multiple topical administrations of BPR277 in patients with atopic dermatitis and Netherton syndrome – CBPR277X2101

October 2011 to February 2013

Sponsor: Astellas Pharma Inc

APPLES: A Prospective Pediatric Longitudinal Evaluation to Assess the Long-Term Safety of Tacrolimus Ointment for the Treatment of Atopic Dermatitis – FHI-03-0-161/FG-506-06-37

June 2010 to October 2012

Sponsor: Novartis

A Prospective 10 Year Observational Registry of Pediatric Subjects (Age Greater Than or Equal to Two to Age Less Than or Equal to 17 Years) With Atopic Dermatitis Who Have Used Pimecrolimus 1% Cream (PEER Registry)

March 2010 to December 2012

Sponsor: Taro Pharmaceuticals USA, Inc./Novum

A Randomized, Double-Blind, Placebo Controlled, Parallel Design, Multiple-Site Clinical Study to Evaluate the Bioequivalence of Two Tacrolimus 0.1% Topical Ointment Formulations in Patients With Moderate to Severe Atopic Dermatitis – TACR-0707

November 2008 to August 2009

Sponsor: Ceragenix

A Prospective, Randomized, Investigator-Blind, Controlled, Pilot Study Comparing The Effect of the EpiCeram Device versus Conservative Standard of Care Therapy Utilizing Mid-Strength Topical Steroid XXXXX in the Treatment of Atopic Dermatitis in Pediatric Subjects

November 2006 to May 2007

Sponsor: Cutanea Life Sciences, Inc.

Phase: 3

A Phase III Open-Label Extension Study to Evaluate the Long-Term Safety of Omiganan Topical Gel in Subjects with Rosacea - CLS001-CO-PR-006

December 2015 to March 2018

Sponsor: Cutanea Life Sciences, Inc.

Phase: 2

A Phase II, Randomized, Vehicle-Controlled, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Three Once-Daily CLS001 Topical Gels Versus Vehicle Administered for 12 Week to Subjects with Papulopustular Rosacea – CLS001-CO-PR-001

March 2013 to April 2014

Scott A. Fretzin, MD

Sponsor: Galderma Research and Development, Inc.

Phase: 3

A Phase III Randomized, Double-Blind, 12-week Vehicle-Controlled, Parallel-Group Study assessing the efficacy and safety of CD5024 1% cream versus vehicle cream in subjects with papulopustular rosacea, followed by a 40-week investigator-blinding extension comparing the long-term safety of CD5024 1% cream versus azelaic acid 15% gel – RD.06.SPR-18171

March 2012 to September 2013

Sponsor: Galderma

Phase: 4

A Phase IV, Open-Label, Multicenter, Community-Based, 12-Week Trial Assessment of Effectiveness, Safety, and Subject Satisfaction With Oracea® [Doxycycline, USP] Capsules 40 mg (30 mg Immediate Release & 10 mg Delayed Release Beads) When Used as Monotherapy or as Add-On Therapy to Existing Topical Regimens for the Treatment of Rosacea – GLI.04.SPR.US10120

June 2009 to November 2009

Sponsor: Medicis

Phase: 4

R# Trial, Phase IV Evaluation of the Effectiveness of XXXXX in Patients with Rosacea

December 2000

Sponsor: Symbio

Phase: 2

A Multicenter, Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled Study of the Safety and Efficacy of DFD-03 Lotion in the Treatment of Acne Vulgaris for 12 Weeks DFD-03-CD-006

August 2017- July 2018

Sponsor: Foamix

Phase: 2

A Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 for 12 Weeks in the Treatment of Moderate-to-Severe Acne Vulgaris FX2017-22

July 2017- September 2018

Sponsor: Foamix

Phase: 3

A Randomized, Double-Blind Study to compare the efficacy, safety and Long-term safety of topical administration of FMX-101 for 1 year in the treatment of Moderate-to-Severe Acne Vulgaris. FX2014-05

July 2016- April 2017

Sponsor: Valeant

Phase: 1B

A Phase Ib Open-Label, Randomized Study Evaluating the Absorption and Systemic Pharmacokinetics of Topically Applied IDP-123 Lotion in Comparison with Tazorac Cream 0.1% in Subjects with Acne Vulgaris under Maximal Use Conditions. – V01-121A-501

June 2016- March 2017

Sponsor: Dow Pharmaceutical Sciences

Phase: 3

A Phase III, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, 2-Arm, Parallel Group Comparison Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris - V01-121A-302

October 2015 to May 2017

Sponsor: Ranbaxy

Phase: 4

A Phase IV Open-Label Study Evaluating the Long-term Efficacy, Quality of Life, and Safety of ABSORICA® (isotretinoin) Capsules Administered Without Food in Patients With Severe Recalcitrant Nodular Acne - ABS1517LT

February 2015 to April 2018

Sponsor: Allergan (North America)

Phase: 3

A Safety and Efficacy Study to Compare Dapsone Dermal Gel with Vehicle Control in Patients with Acne Vulgaris – 225678-007

January 2014 to January 2015

Scott A. Fretzin, MD

Sponsor: Taro Pharmaceuticals

A Multicenter, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing Taro Pharmaceuticals, Inc.'s Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% to the Reference Listed Acanya® (Clindamycin Phosphate and Benzoyl Peroxide) Gel, 1.2%/2.5%, and both Active Treatments to a Vehicle Control in the Treatment of Acne Vulgaris - CLBG1210

January 2013 to February 2014

Sponsor: Warner Chilcott

A Randomized, Multicenter, Double-Blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of 3 Different doses of a Novel Tetracycline, Compared to Placebo in Treatment of Facial Acne Vulgaris – PR-10411

May 2012 to December 2012

Sponsor: Dow Pharmaceutical Sciences, Inc

Phase: 2

A Phase II, Multicenter, Randomized, Double-Blind, Dose-Ranging Study to Evaluate IDP-107 Versus Placebo in the Treatment of Severe Acne Vulgaris with Nodules – DPSI-IDP-107-P2-02

August 2010 to June 2011

Sponsor: Stiefel, a GSK company

Phase: 3

A Phase III, Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Acne Vulgaris – W0260-301

October 2009 to January 2011

Sponsor: Cipher Pharmaceuticals

Phase: 3

A Double-Blind, Randomized, Phase III, Parallel Group Study Evaluating the Efficacy and Safety of CIP-Isotretinoin in Patients with Severe Recalcitrant Nodular Acne – ISOCT.08.01

October 2009 to October 2011

Sponsor: Stiefel Laboratories

Phase: 3

A Phase III, Multicenter, Randomized, Double-blind, Active and Vehicle-Controlled Study of the Safety and Efficacy of Duac Low-Dose Gel Versus Clindamycin Gel versus Benzoyl Peroxide Gel versus Vehicle Gel in Subjects with Acne Vulgaris – W0261-301

October 2008 to 2009

Sponsor: Novum Pharmaceutical Research

A Randomized, Double-Blind, Multiple-Site, Placebo-Controlled Study Comparing XXXXX to XXXXX in the Treatment of Moderate to Severe Acne Vulgaris.

October 2007 to September 2008

Sponsor: Galderma R&D Inc.

A Multi-Center, Randomized, Double-Blind, Parallel Group Study to Demonstrate Safety and Efficacy of a Fixed-Combination of a Topical Retinoid and Benzoyl Peroxide 2.5% Gel Compared With the Monads and Corresponding Topical Gel Vehicle.

October 2006 to June 2007

Sponsor: Johnson & Johnson

Phase: 4

A Open-label, Community Based, Phase IV Study to Assess Facial Acne Improvement with Use of RETIN-A MICRO® (Tretinoin Gel) Microsphere, 0.04% or 0.1% in a Pump Dispenser

September 2006 to June 2007

Sponsor: Allergan

A Clinical Evaluation of XXXXX Indicated for the Topical Treatment of Patients with Acne Vulgaris, Who Do Not Want To or Are Unable to participate in the iPLEDGE Program.

May 2006 to July 2006

Scott A. Fretzin, MD

Sponsor: Concordia Clinical Research, Inc.

Phase: 4

A Phase IV, Open-Label, Multicenter, Community-based, 4-Week Trial Assessing Efficacy, Tolerance to Treatment, and Subject Satisfaction with XXXXX.

March 2006 to June 2006

Sponsor: Elorac, Inc

Phase: 2

A Double-Blind, Randomized, Placebo-Controlled Dose-Ranging Study Evaluating the Efficacy and Safety of Once Weekly High Dose Oral Finasteride in the Treatment of Severe Nodulocystic Acne - EL-1006-01-01

September 2015 to June 2017

Sponsor: Novartis

Phase: 2/3

Novartis Pharmaceuticals trial entitled: A multi-center, randomized, double-blind, active and placebo-controlled study to investigate the efficacy and safety of Igelizumab (QGE031) in the treatment of Chronic Spontaneous Urticaria (CSU) in adolescents and adults inadequately controlled with H1-antihistamines

December 2018- Present

Sponsor: Novartis Global Clinical Dev.

Phase: 2B

A Multicenter, Randomized, Double-Blind, Placebo and Active-Controlled Phase IIb Dose-Finding Study of QGE031 as add-on therapy to investigate the efficacy and safety in patients with Chronic Spontaneous Urticaria (CSU) – CQGE031C2201

July 2015 to June 2016

Sponsor: Pfizer

Phase: 2A

C2501007: A PHASE 2A, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 16 WEEK STUDY EVALUATING THE SAFETY AND EFFICACY OF PF-06650833, PF-06700841 AND PF-06700847 IN ADULTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA

December 2019- Present

Sponsor: Novartis

Phase: 2/3

Novartis Pharmaceuticals trial entitled: A randomized, double-blind, multicenter study assessing short (16 week) and long-term efficacy (up to 1 year), safety, and tolerability of 2 subcutaneous secukinumab doses regimens in adult patients with moderate to severe hidradenitis suppurative (SUNRISE)

Protocol No.: CAIN457M2302

January 2019- Present

Sponsor: XBiotech

Phase: 2

2019-PT047: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa

August 2019- Present

Sponsor: ChemoCentryx

Phase2

CL016_168: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan in Subjects with Moderate to Severe Hidradenitis Suppurativa

May 2019 - Present

Sponsor: Target-Derm

Phase: 2

CL016_168: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan in Subjects with Moderate to Severe Hidradenitis Suppurativa

April 2019- Present

Scott A. Fretzin, MD

Sponsor: Novartis Institutes for BioMedical

Phase: 2

A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to evaluate the clinical efficacy, safety, tolerability, dose relation, atopic etics and pharmacodynamics of CJM112 in moderate to severe chronic hidradenitis suppurativa patients – CCJM112X2202

July 2015 to February 2017

Sponsor: AbbVie

An Observational, Multicenter Disease Registry to Evaluate Clinical Practice Trends and Outcomes in Adult and Adolescent Patients with Hidradenitis Suppurativa – UNITE – H13-147

May 2014 to February 2020

Sponsor: AstraZeneca

Phase: 2A

A Phase IIa, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Safety, Tolerability and Preliminary Efficacy of MEDI8968 in Subjects with Moderate to Severe Hidradenitis Suppurativa – D5440C00001

June 2013 to December 2014

Sponsor: Genentech, Inc.

Phase: 4

A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients with Chronic Idiopathic Urticaria – ML29510

July 2015 to June 2017

Sponsor: Genentech

Phase: 3

A Phase III, Multicenter, Randomized, Double-Blind, Dose-Ranging, Placebo-Controlled Study to Evaluate the Efficacy, Response, Curation and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Antihistamine Treatment (H1) – Q4882g

April 2011 to September 2012

Sponsor: Athenex

Phase: 3

A Phase III, Double-Blind, Vehicle-Controlled, Randomized, Parallel Group, Multicenter, Efficacy and Safety Study of KX2-391 Ointment 1% in Adult Subjects with Actinic Keratosis on the Face or Scalp KX01-AK-004

October 2017- November 2019

Sponsor: Therapeutics Inc

Phase: 3

A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Comparison Study to Determine the Therapeutic Equivalence of a Generic Ingenol Mebutate Gel, 0.015% and Picato Gel, 0.015% in Subjects with Actinic Keratosis on the Face or Scalp 094-8152-301

July 2016 to May 2017

Sponsor: LEO Pharma A/S

Phase: 3

Efficacy and Safety of Ingenol Mebutate Gel in Field Treatment of Actinic Keratosis on Full Face, Balding Scalp or Approximately 250 cm² on the Chest – LP0105-1032

May 2015 to April 2017

Sponsor: Perrigo UK FINCO Limited Par.

Phase: 3

A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study to Compare Perrigo UK Finco Ingenol Mebutate Topical Gel 0.015% to Leo Pharma Inc. Picato® Topical Gel 0.015% (Ingenol Mebutate Topical Gel 0.015%), and Both Active Treatments to a Vehicle Control in the Treatment of Actinic Keratosis on the Head Region (Face or Scalp) – PRG-NY-14-019

March 2015 to December 2015

Sponsor: LEO Pharma A/S

Phase: 3

Safety of LEO 43204 0.018%, 0.037% and 0.1% for actinic keratosis applied once daily for three consecutive days on face/chest, scalp and trunk/extremities, respectively – LP0084-1148

February 2015 to September 2015

Scott A. Fretzin, MD

Sponsor: Actavis Mid Atlantic, LLC **Phase: 3**

A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Comparison Study to Determine the Therapeutic Equivalence of a Generic Ingenol Mebutate Gel, 0.05% and Picato® Gel, 0.05% in Subjects with Actinic Keratosis on the Trunk or Extremities – 094-8151-301
January 2015 to January 2016

Sponsor: LEO Pharma A/S **Phase: 2**

Safety and efficacy of escalating doses of ingenol mebutate once daily for two or three consecutive days when used on full face, full balding scalp or approximately 250 cm² on the chest in subjects with actinic keratosis Part 1: A Phase 1, multicentre, open-label, dose escalation 2-week trial Part 2: A Phase 2, multicentre, randomised, double-blind, parallel group, vehicle-controlled, 8-week trial – LP0105-1012
December 2013 to August 2014

Sponsor: Actavis Elizabeth LLC **Phase:**

A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Comparison Study to Determine the Therapeutic Equivalence of Generic Imiquimod Cream, 2.5% and Zyclara™ (imiquimod) Cream 2.5% in Subjects with Actinic Keratoses – 094-3153-301
October 2013 to June 2014

Sponsor: Peplin Operations

A 12 Month, Long-term Follow-up Study of Patients With Actinic Keratoses on the Head (Face or Scalp) Who Have Completed Day 57 in Studies PEP005-016 or PEP005-025 - PEP005-030
August 2009 to January 2011

Sponsor: Peplin Operations **Phase: 2**

A Phase II, Multi-Center, Randomized, Parallel Group, Double-Blind, Vehicle-Controlled Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, 0.05% in Patients with Actinic Keratoses on Non-Head Locations - PEP005-028
July 2009 to January 2011

Sponsor: Peplin Operations **Phase: 3**

A Phase III Multi-Center, Randomized, Parallel Group, Double-Blind, Vehicle-Controlled Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, 0.15% in Patients with Actinic Keratoses on the Head (Face or Scalp) – PEP005-016
June 2009 to January 2011

Sponsor: Peplin Operations **Phase: 3**

A Phase III, Multi-Center, Open-Label Study to Evaluate the Safety and Efficacy of PEP005 (Ingenol Mebutate) Gel, 0.05% in Patients With Actinic Keratoses on Non-head Locations (Trunk and Extremities) – PEP005-028
June 2009 to January 2011

Sponsor: Graceway Pharmaceuticals, LLC **Phase: 4**

A Phase IV, Open-Label Safety and Pharmacokinetic Study of Aldara (Imiquimod) Cream, 5% for One, Two, or Three Treatment Cycles to Surface Areas Greater Than 25 cm² With Actinic Keratosis
September 2005 to June 2007

Sponsor: 3M **Phase: 3B**

A Phase IIIb, Open-Label Effectiveness and Safety Study of Imiquimod 5% Topical Cream in the Treatment of Actinic Keratosis.
April 2004 to August 2004

Sponsor: XOMA (US) LLC

An Open-label Safety Extension Study of Gevokizumab in Active Inflammatory, Erosive Osteoarthritis of the Hand - X052161
September 2013 to February 2015

Scott A. Fretzin, MD

Sponsor: XOMA (US) LLC

Phase: 2

A Phase II Proof-of-Concept Study of Gevokizumab in Subjects with Inflammatory Erosive Osteoarthritis of the Hand - X052162

July 2013 to March 2014

Sponsor: XOMA (US) LLC

Phase: 2

A Phase II Proof-of-Concept Study of gevokizumab in active inflammatory, erosive osteoarthritis of the hand – X052160

May 2013 to March 2014

Sponsor: Fairbanks Institute for Health

Multicenter Research Study to Build a Repository that will allow Researchers to Study Chronic Diseases in the Population of Central Indiana

July 2013 to May 2014

Sponsor: Eli Lilly and Company

A Randomized, Double-Blind, Placebo-Controlled Parallel Study with an Open-Label Extension to Assess the Impact of Testosterone Solution on Total Testosterone, Sex Drive and Energy in Hypogonadal Men – I5E-MC-TSAT

June 2013 to June 2015

Sponsor: Biogen

Phase: 2

A 2-Part Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects with Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects with Active Cutaneous Lupus Erythematosus with or without Systemic Manifestations. 230LE201

August 2016- Present

Sponsor: Janssen Research and Develop

A Cross-Sectional Study in Subjects With Active Cutaneous Lupus Erythematosus – NOCOMPOUNDLUN0001

June 2013 to October 2014

Sponsor: Pfizer

A Randomized, Subject and Investigator-Blinded, (Sponsor-Open), Placebo-Controlled dose Escalation Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Multiple Doses of PD 0360324 in Subjects with Active Cutaneous Lupus Erythematosus – A6261008

January 2012 to July 2014

Sponsor: Celgene Corporation

Phase: 2

A Phase II, Pilot, Multicenter, Sequential, Ascending Dose Study to Evaluate the Preliminary Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CC-11050 in Subjects With Discoid Lupus Erythematosus and Subacute Cutaneous Lupus Erythematosus – CC-11050-CLE-002

June 2011 to December 2012

Sponsor: Takeda Global Research and Dev

Phase: 3

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Evaluate Cardiovascular Outcomes of TAK-875, 50 mg in Addition to Standard of Care in Subjects with Type 2 Diabetes and with Cardiovascular Disease or Multiple Risk Factors for Cardiovascular Events – TAK-875_306

February 2013 to February 2014

Sponsor: Merck & Co., Inc.

Phase: 3

A Phase III, Randomized Double-Blind, Active-Comparator Controlled, Clinical Trial to Study the Efficacy and Safety of XXXXX for the Treatment of Patients With Type 2 Diabetes Mellitus

September 2007 to October 2008

Scott A. Fretzin, MD

Sponsor: GlaxoSmithKline

Phase: 2B

A Phase IIb, 16-week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose-Ranging Study to evaluate the efficacy, safety and tolerability of multiple doses and multiple treatment regimens of Albiglutide (GSK716155) with Byetta as an open-label active reference, in subjects with Type 2 Diabetes Mellitus

April 2007 to February 2008

Sponsor: Eli Lilly and Company

The DURABLE Trial: Assessing the Durability of Basal vs. Lispro Mix 25 Insulin Efficacy.

March 2006 to October 2008

Sponsor: Novartis Pharmaceuticals

A 12-week Treatment, Multi-Center, Randomized, Double-Blind, Parallel-Group, Placebo and Active Controlled Study to assess the efficacy, safety, and tolerability of QVA149 (indacaterol maleate / glycopyrronium bromide) in COPD patients with moderate to severe airflow limitation – CQVA149A2336

January 2013 to May 2014

Sponsor: Forest Laboratories

Phase: 3

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Tolerability of 2 Doses of Acridinium Bromide Compared With Placebo for 12 Weeks in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease Followed by a 40-Week Evaluation of the 2 Acridinium Bromide Dose – LAS-MD-38

March 2010 to November 2010

Sponsor: Novartis

Phase: 3B

A Phase IIIb, Randomized, Double-Blind, Controlled, Parallel Group, 12-week Treatment Study to compare the efficacy and safety of the combination of indacaterol 150 µg once daily with open label tiotropium 18 µg once daily vs open label tiotropium 18 µg once daily in patients with moderate-to-severe chronic obstructive pulmonary disease – CQAB149B2341

February 2009 to April 2010

Sponsor: Novartis

A 12-week Treatment, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Assess the Efficacy and Safety of XXXXX in Patients with Chronic Obstructive Pulmonary Disease

February 2008 to August 2009

Sponsor: Novartis

Phase: 2/3

A Phase II/III, 26-Week Treatment, Multicenter, Randomized, Double-Blind, Double Dummy, Placebo-Controlled, Adaptive, Seamless, Parallel-Group Study to Assess the Efficacy, Safety and Tolerability of Two Doses of Indacaterol (Selected From 75, 150, 300 & 600 µg o.d.) in Patients With Chronic Obstructive Pulmonary Disease Using Blinded Formoterol (12 µg b.i.d) and Open Label Tiotropium (18 µg o.d.) as Active Controls

March 2007 to February 2009

Sponsor: GlaxoSmithKline

Phase: 4

A 6-month Safety and Benefit Study of inhaled fluticasone propionate/salmeterol combination versus inhaled fluticasone propionate in the treatment of 6,200 pediatric subjects 4-11 years old with persistent asthma, Phase IV – SAS115358

September 2012 to October 2013

Sponsor: GlaxoSmithKline

A Safety and Efficacy Study of Inhaled Fluticasone Propionate/Salmeterol Combination versus Inhaled Fluticasone Propionate in the Treatment of Adolescent and Adult Subjects with Asthma – SAS115359

January 2012 to May 2014

Scott A. Fretzin, MD

Sponsor: GlaxoSmithKline

Phase: 3

A Phase III, Long-Term, Randomized, Double-Blind, Parallel Group Study of Fluticasone Furoate/GW642444 Inhalation Powder Once-Daily and Fluticasone Furoate Inhalation Powder Once-Daily in Subjects with Asthma – HZA106837

March 2010 to November 2011

Sponsor: Merck and Co., Inc.

Time and Motion Study of Allergen Immunotherapy in the Usual Care Environment in the United States and Canada – A-11107

June 2012 to April 2013

Sponsor: Merck and Co., Inc.

Phase: 2

A Phase II Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Immunogenicity of V212 in Adult Patients with Autoimmune Disease – 009-00

February 2012 to December 2012

Sponsor: Novartis

A 6-month, Randomized, Active Comparator, Open-Label, Multi-Center Study to Evaluate Patient Outcomes, Safety and Tolerability of Fingolimod 0.5 mg/day in Patients with Relapsing Forms of Multiple Sclerosis who are candidates for MS therapy change from Previous Disease Modifying Therapy (EPOC) – CFTY720DUS01

July 2011 to April 2012

Sponsor: Hisamitsu Pharmaceutical Co., Inc.

A Randomized, Double-Blind, Parallel-Group, Multicenter, Placebo-Controlled Study of the Safety and Efficacy of HTU-520 in the Treatment of Mild to Moderate Distal Subungual Onychomycosis of the Toenail – HTU-520-US01

June 2011 to May 2013

Sponsor: Eli Lilly & Co.

Phase: 2

A Phase II study of LY900010 (LY2452473 + Tadalafil) in the Treatment of Men With Erectile Dysfunction – I4K-MC-GPEC

October 2010 to January 2012

Sponsor: Eli Lilly & Co.

Biomarker Study of the Smoothened Pathway in Healthy Volunteers – I4J-MC-HHBA

April 2010 to June 2010

Sponsor: Eli Lilly and Company

Phase: 2

A Phase II, Weight Loss Efficacy Study in Overweight/Obese Men and Women – I1L-MC-GAEB

October 2009 to September 2010

Sponsor: Inhibitex

Phase: 2

A Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Comparative Study of FV-100 vs. Valacyclovir in Patients with Herpes Zoster – INH-FV1-005

June 2009 to December 2010

Sponsor: GlaxoSmithKline

A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE) – LPL100601

February 2009 to August 2013

Sponsor: Novartis

An 8 Week Randomized, Double-Blind, Parallel Group, Multi-Center, Active Controlled Study to Evaluate the Antihypertensive Efficacy and Safety of Aliskiren Administered in Combination With Valsartan Versus Valsartan Alone in Patients With Stage 2 Systolic Hypertension and Type 2 Diabetes Mellitus – CSPP100A2409

Scott A. Fretzin, MD

November 2008 to June 2010

Sponsor: Pharming Technologies B.V.

Phase: 2

A Phase II, Randomized, Placebo-Controlled, Double-Blind Study of the Safety and Efficacy of XXXXX for the Treatment of Acute Attacks in Patients with Hereditary Angioedema – C1 1205-01

July 2008 to January 2010

Sponsor: Eli Lilly and Company

Phase: 1

A Phase I Study to Quantify the Number of Circulating Endothelial Cells in Patients with Severe Sepsis

October 2007 to November 2009

Sponsor: Pfizer

Phase: 4

A Phase IV, Randomized, Double Blind, Parallel-Group Study of Cardiovascular Safety in Osteoarthritis Or Rheumatoid Arthritis Patients With Or At High Risk For Cardiovascular Disease Comparing Celecoxib With Naproxen And Ibuprofen (Precision)

December 2006 to October 2016

Sponsor: Genentech, Inc.

Phase: 1

A Phase I, Double-Blind, Randomized, Placebo Controlled, Multicenter Study Evaluating the Safety and Tolerability of a Multidose Regimen of XXXXX Topically Applied to Superficial or Nodular Basal Cell Carcinoma.

June 2004 to July 2006

Sponsor: CoPharma

Phase: 1/2

A Phase I/II Pilot Study of the Safety and Efficacy of PEN203 in the Treatment of Superficial and Nodular Basal Cell Carcinoma of the Skin.

December 2000 to December 2000

Sponsor: Verrica

Phase: 3

COVE-2: A Phase 3, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of VP-102 in Subjects with Common Warts (Verruca Vulgaris)

November 2019- Present

Sponsor: Aclaris

Phase: 3

A PHASE 3 OPEN LABEL SAFETY STUDY OF A-101 TOPICAL SOLUTION FOR THE TREATMENT OF COMMON WARTS

Dec 2018- March 2019

Aclaris

Phase :3

A PHASE 3 RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, PARALLEL GROUP STUDY OF A-101 TOPICAL SOLUTION APPLIED TWICE A WEEK IN SUBJECTS WITH COMMON WARTS A-101-WART-301

August 2018-November 2019

Cutanea

Phase: 3

A Phase 3, Randomized, Double-Blind, Vehicle-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of CLS006 versus Vehicle in Subjects 2 years of age or older with Cutaneous Common Warts. CLS006-CO-PR-002.

December 2017-January 2019

Aclaris

Phase: 2

A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study Of A-101 Topical Solution Applied Once A Week In Subjects With Common Warts- A-101-Wart-202.

August 2017- April 2018

Scott A. Fretzin, MD

Sponsor: RXi Pharmaceuticals

Phase: 2A

A Prospective, Phase IIa Study to Evaluate the Effectiveness and Safety of DPCP Ointment (Samcyprone) on the Clearance of Verruca Vulgaris (Common Warts) in Subject Ages 18-65 Years. RX-SCP-1502

July 2016 – September 2018

Sponsor: Soligenix

Phase: 3

A Phase III Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Determine the Efficacy of Topical SGX301 (Synthetic Hypericin) and Fluorescent Bulb-Light Irradiation for the Treatment of Cutaneous T-Cell Lymphoma. HPN-CTCL-01

August 2016- Present

Sponsor: Pfizer

Phase: 3

B7981032: A PHASE OPEN- LABEL, MULTI-CENTER, LONG-TERM STUDY INVESTIGATING THE SAFETY AND EFFICACY OF PF-06651600

August 2019- Present

Sponsor: Lilly

Phase: 3

14v-MC-JAIR

A multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients with Severe or Very Alopecia Areata

April 2019- Present

Sponsor: Pfizer

Phase: 2B/3

A PHASE 2B/3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF-06651600 IN ADULT AND ADOLESCENT ALOPECIA AREATA (AA) SUBJECTS WITH 50% OR GREATER SCALP HAIR LOSS

January 2019- Present

Sponsor: Evidera

Phase: Registry

Development of a New Outcome Measure for Alopecia Areata EVA-20417-00

September 2017- Present

Sponsor: Pfizer

Phase: 2A

A Phase IIa, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety Profile of PF-06651600 and PF-0670081 in Subjects with Moderate to Severe Alopecia Areata: B7931005

February 2017- March 2019

Sponsor: Incyte

Phase: 2

A Randomized, Double-Blind, Dose-Ranging Study of INCB018424 Phosphate Cream in Subjects With Vitiligo: 18424-211

October 2017- Present

Sponsor: Novan

Phase: 3

Protocol No: NI-MC301 A Phase 3 Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study Comparing the Efficacy, Safety and Tolerability of SB206 and Vehicle Gel Once Daily in the Treatment of Molluscum Contagiosum

April 2019- Present

Sponsor: Novan

Phase: 2

A Phase 2 Multi-Center, Randomize, Double-Blind, Vehicle-Controlled, Ascending Dose Study of SB206 in Subjects with Molluscum Contagiosum. NI-MC201

January 2018- January 2019

Scott A. Fretzin, MD

Sponsor: Mayne

Phase: 2

A Phase 2 Randomized, Multi-center, Double-blind, Vehicle-controlled, 12-Week, Safety, Efficacy, and Systemic Exposure Study followed by a 12-Week Open-label Extension of Trifarotene (CD5789) Cream HE1 in Adults and Adolescents with Autosomal Protocol number 18-Ich-001

October 2019- Present

Sponsor: Brickell

Phase: 2/3

BBI-4000-CL-301: A Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of Topical Applied Sofpironium Bromide Gel, 15% in Subjects with Axillary Hyperhidrosis (the "Cardigan I Study")

November 2019- Present

Sponsor: CastleBio Science

Phase:

Prospective Development and Validation of a Gene Expression Assay to Predict the Risk of Recurrence Disease in Cutaneous Squamous Cell Carcinoma

August 2019- Present

Clinical Studies conducted outside of Dawes Fretzin Clinical Research Group, LLC

Genital Warts

Sponsor: 3M

Safety and efficacy trial evaluation 5% Imiquimod Cream application to external genital warts and an extended treatment area; *1999-02*

Diabetes

Sponsor: Takeda

Acting Agent: Quintiles, Inc.

An open-label, long-term extension study of voglibose (AO_128) in Type II Diabetes Mellitus patients; *March 1997 to June 1999*

Atopic Dermatitis

Sponsor: Connetics Therapeutics

An open-label, follow-on study of the safety and efficacy of Recombinant Interferon- γ 1b in subjects with moderate to severe atopic Dermatitis; *September 1996 to December 1998*

Atopic Dermatitis

Sponsor: Connetics Therapeutics

A Phase III study of the safety and efficacy of Recombinant Interferon- γ 1b in subjects with moderate to severe atopic Dermatitis; *September 1996 to April 1998*

Diabetes

Sponsor: Takeda

Acting Agent: Covance, Inc

A double-Blind, Placebo-Controlled, Randomized, Dose-Titration Study to Evaluate the Safety and Efficacy of Pioglitazone; *January 1997 to December 1998*

Scalp Psoriasis

Sponsor: Connetics Therapeutics

A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Betamethasone Valerate Foam in Treating Scalp Psoriasis; *April 1997 to December 1997*

Scott A. Fretzin, MD

Bronchitis

Sponsor: Bristol-Myers Squibb

A Double-blind Multicenter Comparative Study of Cefprozil (250mg bid) versus Cefuroxime Axetil (250mg bid) in the Treatment of Bronchitis; *December 1995 to April 1997*

Non-Insulin Dependent Diabetes Mellitus

Sponsor: Parke Davis

A 20-week, Double-Blind, Randomized Study of Troglitazone (CL-991) in patients with Non-Insulin Dependent Diabetes Mellitus; *June 1995 to May 1997*

Diabetes

Sponsor: Takeda

Acting Agent: Quintiles, Inc

A Randomized, Double-Blind, Placebo-Controlled, Six-Month, Safety and Efficacy Trial of 0.1, 0.5, 1, 2, 5 mg TID of Voglibose (AO-128) in Type II Diabetes Mellitus Patients; *October 1996 to December 1997*

Osteoarthritis

Sponsor: Merck

A Double-Blind, Randomized, Multicenter Study to Compare the Safety of Dexibuprofen Lysine with Ibuprofen for Long-Term Treatment of Osteoarthritis; *September 1996 to June 1997*

Rheumatoid Arthritis

Sponsor: Boston Life Sciences, Inc

A Double-Blind, Randomized Study of Therafectin 6 grams/day compared to Placebo in Patients with Rheumatoid Arthritis Withdrawn from their Nonsteroidal Anti-Inflammatory Drug Therapy; *June 1996 to July 1997*

Psoriasis

Sponsor: Sergen, Inc

Phase II Randomized, Double-Blind, Placebo-Controlled Trial of DAB389IL-2 in Patients with Moderate to Severe Plaque-Type Psoriasis; *June 1995 to October 1996*

Xerostomia and Keratoconjunctivitis Sicca

Sponsor: Snowbrand Milk Products, *Acting Agent:* Pharmaco LSR

A pilot study of SNI-2011 in patients with Sjogren's Syndrome experiencing xerostomia and keratoconjunctivitis Sicca; *July 1995 to December 1996*

Intermittent Claudication

Sponsor: Marion Merrell Dow

Dose-Response Evaluation of Beraprost Sodium IR Tablets in Treatment of Intermittent Claudication; *October 1995 to December 1996*

Scott A. Fretzin, MD

Articles and Publications

- Kroman NJ., Sofen H, Fretzin S, Rich P, Zhao Y, Herrera V, Nyirady J, Williams N, Mordin, M, Trying S. **"Secukinumab provides better relief from the impact of psoriasis on daily activities and personal relationships than etanercept: results of two phase 3 placebo-controlled randomized clinical trials in moderate-to-severe psoriasis."** Journal of Dermatological Treatment 2016 Nov 21, Volume 28 2017 Issue 5. 384-389.
- Krueger JG, Fretzin S, Suárez-Fariñas M, Haslett PA, Phipps KM, Cameron GS, McColm J, Katcherian A, Cueto I, White T, Banerjee S, Hoffman RW. **"IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis."** J Allergy Clin Immunol. 2012 Jul;130(1):145-154.e9. Epub 2012 Jun 5.
- Gottlieb, A., Menter, A., Mendelsohn, A., Yaung-Kaung, S., Guzzo, C., Fretzin, S., Kunyetz, R., Kavanaugh, A. **"Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial."** Lancet, 2009 Feb 21; 373:633.
- Papp, K., Bressinck, R., Fretzin, S., Goffe, B., Kempers, S., Gordon, K., Caro, I., Walicke, P., Wang, X., Mentor, A. **"Safety of efalizumab in adults with chronic Moderate to severe plaque psoriasis: A phase IIIb, randomized, controlled trial."** International Journal of Dermatology, May 2006; Vol 45, Number 5: 605-614.
- Crowley, J., Fretzin, S., Sobell, J. **"New Treatment Options for Psoriasis Involving the Hands and Feet."** Biologic Bulletin, March 2006.
- Fretzin, S. **"Recent Advances in the Treatment of Psoriasis with Efalizumab Therapy."** US Dermatology Review, 2006 Issue II: 12-14.
- Fretzin, S. **"Managing Cases of Chronic, Moderate-to-Severe Plaque Psoriasis Involving the Hands and Feet with Raptiva®"** DermPA Today, Spring 2006; Vol 3, Number 1:4-5.
- Fretzin, S. **"Managing Cases of Chronic, Moderate-to-Severe Plaque Psoriasis Involving the Hands and Feet with Raptiva®"** DermNurse, Spring 2006; Vol 2, Number 1:3-4.
- Fretzin, S. **"Managing Cases of Chronic, Moderate-to-Severe Plaque Psoriasis Involving the Hands and Feet with Raptiva®"** Derm Resident, Spring 2006; Vol 5, Number 5:5-6.
- Fretzin S., Crowley, J., Jones, L., Young, M., Sobell, J. **"Successful Treatment of Hand And Foot Psoriasis with Efalizumab Therapy."** Journal of Drugs in Dermatology. October 2006; Vol 5, Issue 9; 838-846.
- Fretzin S., Dawes K. *J Am Acad Dermatol* 2005; 52:P182. Abstract P2745.
- S. Fretzin. **"Answer All Your Patients' Questions About STDs."** Skin Aging 2000; 8 (8) :36-42.
- R. Huff, S. Fretzin, C. Lewis. **"Penile Eruption on a Diabetic Man."** Arch Dermatol 1999; 135 :845.
- R Huff, S. Fretzin. **"Vesicular Eruption on the Chest and Back."** Archives of Dermatology on the internet, 1998.
- S. Fretzin. **"Ringworm and Molluscum Contagiosum."** Indiana Amateur Wrestling News-1997. pg 8.
- M. Fretzin, S. Fretzin, D. Fretzin. **"A Papulonecrotic Eruption in a Young Man."** Arch Dermatol 1997; 133:1453-1458.
- T. Eads, S. Fretzin, C. Lewis. **"Pruritic, Painful Eruption."** Arch Dermatol 1998; 134:231-236
- S. Fretzin. **"Introduction to the Terminology of Ethics."** Ethics Workbook for Dermatology Residency Directors. 1998.

Scott A. Fretzin, MD

- S. Fretzin, W. Beeson, W. Hanke. **"Ignition Potential of the 585 nm Pulsed Dye Laser: Review of the Literature and Safety Recommendations."** Dermatol Surg 1996; 22 699-702.
- G. Westhoven, S. Fretzin, C. Lewis. **"A Woman with Lung Cancer and Exfoliative Dermatitis."** Arch Dermatol 1997; 133: 499-504.
- D. Fretzin, J. Sloan, K. Beer, S. Fretzin. **"Eccrine Syringofibroadenoma: A Clear Cell Variant."** Am.J. of Dermatopathology 1995;17 (6): 591-593
- S. Fretzin, B. Allen, A. Vane Daal, S. Elgin. **"A Drosophila melanogaster H3.3 cDNA Encodes a Histone Variant Identical with the Vertebrate H3.3."** Gene. 107 (1991) 341-342.
- F. Booyse, R. Bruce, M. Grover, S. Fretzin, J. Karkov, H. Modi, L. Casey. **"Rapid Release of Plasminogen Activators From Cultured Human Umbilical Vein Endothelial Cells."** Blood. 66#5 (1985).
- JC. Cather, C. Ryan, K. Meeuwis, AJ. Potts Bleakman, AN. Naegeli, E. Edson-Heredia, JL. Poon, C. Jones, AN. Wallace, L. Guenther, S. Fretzin. **"Patients' Perspective on the Impact of Genital Psoriasis: A Qualitative Study"**

Presentations/Posters

The American Academy of Dermatology Meeting. D. Rosmarin, S. Fretzin, L. Strowd, M. Casillas, A. DeLozier, Z. Dawson, S. Chen, N. Lu, J Thyssen. Rapid Improvement in Skin Pain and its Impact on Quality of Life in Adult Patients with Moderate-to-Severe Atopic Dermatitis From a Double-Blind, Placebo-Controlled Baricitinib Phase 3 Study. March 2021

The American Academy of Dermatology Meeting. A. Armstrong, K. Callis Duffin, A. Van Voorhees, A. Blauvelt, S. Fretzin, A. Jacobson. Improvements in Quality of Life by Categories of Skin Clearance in Clinical Trials of Brodalumab Through 52 Weeks. March 2020

Maui Derm for Dermatologist. 120-Week Efficacy. A. Blauvelt, S. Fretzin, M. Bettencourt, C. Leonardi, R. Pillai, A. Jacobson. Post Hoc Analysis of Long-term Efficacy and Safety of Brodalumab by Baseline Disease Severity. January, 2019

XXIV World Congress of the ISSVD. J. Clay Cather, A. Potts Bleakman, C Ryan, J. Ling Poon, B. Malatstnic, A. Naegeli, S. Fretzin. The Burden and Impact of Moderate-to-Severe Genital Psoriasis on Female Patients. September, 2017

The American Academy of Dermatology Meeting. C.Ryan, K. Meeuwis, A. Potts Bleakman, A. Naegeli, J. Ling Poon, K. Hollister, S. Fretzin. The Burden of Moderate-To-Severe Genital Psoriasis: Patients' Perspective on Symptoms. March, 2017

The American Academy of Dermatology Meeting. J. Clay Cather, A. Potts Bleakman, A. Naegeli, J. Ling Poon, A. Wallace, K. Hollister, S. Fretzin. Patients' Perspective on the Impact of Moderate-To-Severe Genital Psoriasis. March, 2017

The American Academy of Dermatology Meeting. N. Korman, H. Sofen, P. Rich, S. Fretzin, Y. Zhao, V. Herrera, M. Mordin, N. Williams, J. Nyirady, S. Tyring. Secukinumab Provides More Effective Relief From Psoriasis Impact on Personal

Scott A. Fretzin, MD

Relationships and Influence on Clothes Worn Than Etanercept and Placebo. March, 2016

The American Academy of Dermatology Meeting. H. Sofen, N. Korman, P. Rich, S. Fretzin, Y. Zhao, V. Herrera, B. Sherif, L. McLeod, J. Nyirady, S. Tying. Secukinumab Provides More Effective Relief From Skin-Related Quality-of-Life Impact Than Placebo in Moderate to Severe Psoriasis. March, 2016

The American Academy of Dermatology Meeting. S. Tying, H. Sofen, S. Fretzin, P. Rich, Y. Zhao, V. Herrera, B. Sherif, N. Williams, J. Nyirady, N. Korman. Secukinumab Provides More Effective Relief From Skin-Related Quality-of-Life Impact Than Etanercept in Moderate to Severe Psoriasis. March, 2016

The American Academy of Dermatology Meeting. A. Armstrong, S. Fretzin, S. McBride, R. Burge, B. Zhu, E. Edson-Heredia, F. Zhao, A. Beselin, K. Gordon. Treatment with ixekizumab over 60 weeks provides sustained improvements in work productivity and activity levels: Results from UNCOVER-1, a Phase 3 trial in patients with moderate-to-severe psoriasis. March, 2016

The American College of Rheumatology Annual Meeting. M. Cesaroni, J. Jordan, J. Schreifer, M. Chevrier, G. Wang, C. Calderon, A. Piantone, I. Gourley, S. Cohen, S. Fretzin, A. Wonzniacka, VP. Werth, J. Benson. Identification of Molecular Biomarkers to Distinguish Systemic Lupus Erythematosus with Skin Involvement from Discoid Lupus Erythematosus and Subacute Cutaneous Erythematosus: Provisional Results from Cross-Sectional Studies [abstract]. *Arthritis Rheumatol*, 2015; 67 (suppl 10), November 6-11, 2015

The American Academy of Dermatology Meeting. S. Philipp, S. Fretzin, M. Notter, C. Papavassilis. Secukinumab Effect on Functional Ability in Subjects With Moderate-to-Severe Plaque Psoriasis and Psoriatic Arthritis: A Subanalysis From the FIXTURE Study. March, 2014

World Congress of Dermatology. C. Leonardi, J. Sobell, S. Fretzin, H. Sofen, T. Hamilton, Y. Chen, C. Ivor, A. Menter. Phase IV Study to Evaluate the Safety and Efficacy of Efalizumab in the Treatment of Hand and Foot Plaque Psoriasis. October, 2007

Presentations/Posters (Cont)

68th SID Annual Meeting. A. Ehrlich, S. Fretzin, W. Werther, Y. Chen, I. Caro, D. Pariser. Prevalence of Cardiovascular Risk Factors by Psoriasis Severity in Biologic-Treated Patients: The RESPONSE Cohorts. May 9-12, 2007.

Australasian College of Dermatologists 39th Annual Scientific Meeting. S. Fretzin, K. Dawes, AC Rundle, I Caro. Safety of a topically applied novel small molecule inhibitor of the Hedgehog signaling pathway in subjects with basal cell carcinoma. May 14-17, 2006.

The American Academy of Dermatology Meeting (64th Annual). J. Sobell, S. Fretzin. Case studies of efalizumab in hand and foot psoriasis. March 3-7, 2006.

Scott A. Fretzin, MD

The American Academy of Dermatology Meeting. S. Fretzin, A. Menter, R. Langley, D. Cohen. Therapeutic Strategies and Treatments for Psoriasis (CME/CD-ROM). February, 2005.

The American Academy of Dermatology Meeting. S. Fretzin, K. Dawes. Efficacy and Safety of Efalizumab for Patients with Palmoplantar Pustulosis. February, 2005.

The American Academy of Dermatology Meeting. S. Fretzin, J. Cotton, A. Hood. Aleukemic Lymphoblastic Leukemia Cutis in a 14 month-old girl. San Francisco, California. 1997.

The American Society for Dermatopathology Meeting. J. Cotton, S. Fretzin, A. Hood. Cutaneous Lymphoblastic Lymphoma in children. Two case reports and review of the literature. San Francisco, California. March, 1997.

The United States and Canadian Academy of Pathology Meeting. J. Cotton, S. Fretzin, R. Neiman. Cutaneous Lymphoblastic Lymphoma in children. Two case reports and review of the literature. Orlando, Florida. March 1997.

St. Vincent's Hospital Dermatopathology Conference. S. Fretzin. Degos' Syndrome. January 1997.

St. Vincent's Hospital Dermatopathology Conference. S. Fretzin. Well's Syndrome. September 1996.

The American Academy of Dermatopathology Meeting, 1996. S. Fretzin, H. Faust. Atypical Cutaneous reaction to Benazepril with histologic features of Mycosis Fungoides.

The American Society for Cell Biology Regional Meeting. Poster Presentation. S. Elgin, A. Van daal, S. Fretzin, E. White, M. Gorovsky. "Histone Variants H2Avd and H3.3 of *Drosophila melanogaster*." March, 1990.

UCLA Symposium on Transcriptional Control of Cell Growth. A. Van daal, S. Fretzin, E. White, M. Gorovsky, S. Elgin. "Histone Variants H1Avd and H3.3. of *Drosophila melanogaster*." January, 1990.

Other Research Experience

- 1988-90 Washington University of St. Louis, Dept. of Biology, Sarah C. Elgin, Ph.D.; Characterization of *Drosophila melanogaster* Histone Variant Gene.
- 1986-88 Barnes Hospital, Dept. of Dermatology, Eugene Bauer, M.D.; Collagenase assays for research in Epidermolysis Bullosa.
- 1987 Michael Reese Hospital, Dept. of Immunology, Enrique Beckman M.D.; Gene Rearrangement of Lymphomas.
- 1985-86 Michael Reese Hospital, Dept. of Immunology, Françoise Booyse, Ph.D.; Release of Plasminogen activators from human endothelial cells.

Scott A. Fretzin, MD

License/Certifications

Board Certified in Dermatology, 1997

Indiana State License #01044060

ACLS Certified

CITI Certification, March 2010, February 2012, January 2014, January 2015, February 2016, January 2017, December 2018, November 2019, November 2021

Professional Societies

American Academy of Dermatology

Indiana Dermatologic Society

American Medical Association